Form 4 for IMDX Insight Molecular Diagnostics Inc.

Accepted 2024-10-04 00:00:00 ET · period of report 2024-10-02 · accession 0000919574-24-005764 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-10-04	2024-10-02	IMDX	BROADWOOD CAPITAL INC	10%	P - Purchase	—	0	6.24M	New	—
	2024-10-04	2024-10-02	IMDX	BROADWOOD CAPITAL INC	10%	P - Purchase	$2.95	+1.32M	6.24M	+27%	+$3.88M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock, no par value	2024-10-02	P	A	0	$0.00	6,244,405	I	—	—
2	Common	Common Stock, no par value	2024-10-02	P	A	1,315,339	$2.95	6,244,405	D Footnote	—	—	(F3) On October 2, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 1,315,339 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a private placement for a total purchase price of $3,877,619.38, or $2.948 per Common Share. (F1) The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.